Old dog, new tricks: Novel cardiac targets and stress regulation by protein kinase G

Peter P. Rainer, David A Kass

Research output: Contribution to journalReview article

Abstract

The second messenger cyclic guanosine 3′5′ monophosphate (cGMP) and its downstream effector protein kinase G (PKG) have been discovered more than 40 years ago. In vessels, PKG1 induces smooth muscle relaxation in response to nitric oxide signalling and thus lowers systemic and pulmonary blood pressure. In platelets, PKG1 stimulation by cGMP inhibits activation and aggregation, and in experimental models of heart failure (HF), PKG1 activation by inhibiting cGMP degradation is protective. The net effect of the above-mentioned signalling is cardiovascular protection. Yet, while modulation of cGMP-PKG has entered clinical practice for treating pulmonary hypertension or erectile dysfunction, translation of promising studies in experimental HF to clinical success has failed thus far.With the advent of new technologies, novel mechanisms of PKG regulation, including mechanosensing, redox regulation, protein quality control, and cGMP degradation, have been discovered. These novel, non-canonical roles of PKG1 may help understand why clinical translation has disappointed thus far. Addressing them appears to be a requisite for future, successful translation of experimental studies to the clinical arena.

Original languageEnglish (US)
Pages (from-to)154-162
Number of pages9
JournalCardiovascular Research
Volume111
Issue number2
DOIs
StatePublished - 2016

Fingerprint

Cyclic GMP-Dependent Protein Kinases
Cyclic GMP
Heat-Shock Proteins
Dogs
Heart Failure
Muscle Relaxation
Second Messenger Systems
Erectile Dysfunction
Pulmonary Hypertension
Quality Control
Oxidation-Reduction
Smooth Muscle
Nitric Oxide
Theoretical Models
Blood Platelets
Blood Pressure
Technology
Lung
Proteins

Keywords

  • Cardiac mechanosensing
  • CGMP-dependent protein kinase type 1
  • Phosphodiesterase
  • Proteasome
  • Protein kinase G
  • Redox regulation

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Old dog, new tricks : Novel cardiac targets and stress regulation by protein kinase G. / Rainer, Peter P.; Kass, David A.

In: Cardiovascular Research, Vol. 111, No. 2, 2016, p. 154-162.

Research output: Contribution to journalReview article

@article{ae38e4ad9a3d4a598563b1fe674490bd,
title = "Old dog, new tricks: Novel cardiac targets and stress regulation by protein kinase G",
abstract = "The second messenger cyclic guanosine 3′5′ monophosphate (cGMP) and its downstream effector protein kinase G (PKG) have been discovered more than 40 years ago. In vessels, PKG1 induces smooth muscle relaxation in response to nitric oxide signalling and thus lowers systemic and pulmonary blood pressure. In platelets, PKG1 stimulation by cGMP inhibits activation and aggregation, and in experimental models of heart failure (HF), PKG1 activation by inhibiting cGMP degradation is protective. The net effect of the above-mentioned signalling is cardiovascular protection. Yet, while modulation of cGMP-PKG has entered clinical practice for treating pulmonary hypertension or erectile dysfunction, translation of promising studies in experimental HF to clinical success has failed thus far.With the advent of new technologies, novel mechanisms of PKG regulation, including mechanosensing, redox regulation, protein quality control, and cGMP degradation, have been discovered. These novel, non-canonical roles of PKG1 may help understand why clinical translation has disappointed thus far. Addressing them appears to be a requisite for future, successful translation of experimental studies to the clinical arena.",
keywords = "Cardiac mechanosensing, CGMP-dependent protein kinase type 1, Phosphodiesterase, Proteasome, Protein kinase G, Redox regulation",
author = "Rainer, {Peter P.} and Kass, {David A}",
year = "2016",
doi = "10.1093/cvr/cvw107",
language = "English (US)",
volume = "111",
pages = "154--162",
journal = "Cardiovascular Research",
issn = "0008-6363",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Old dog, new tricks

T2 - Novel cardiac targets and stress regulation by protein kinase G

AU - Rainer, Peter P.

AU - Kass, David A

PY - 2016

Y1 - 2016

N2 - The second messenger cyclic guanosine 3′5′ monophosphate (cGMP) and its downstream effector protein kinase G (PKG) have been discovered more than 40 years ago. In vessels, PKG1 induces smooth muscle relaxation in response to nitric oxide signalling and thus lowers systemic and pulmonary blood pressure. In platelets, PKG1 stimulation by cGMP inhibits activation and aggregation, and in experimental models of heart failure (HF), PKG1 activation by inhibiting cGMP degradation is protective. The net effect of the above-mentioned signalling is cardiovascular protection. Yet, while modulation of cGMP-PKG has entered clinical practice for treating pulmonary hypertension or erectile dysfunction, translation of promising studies in experimental HF to clinical success has failed thus far.With the advent of new technologies, novel mechanisms of PKG regulation, including mechanosensing, redox regulation, protein quality control, and cGMP degradation, have been discovered. These novel, non-canonical roles of PKG1 may help understand why clinical translation has disappointed thus far. Addressing them appears to be a requisite for future, successful translation of experimental studies to the clinical arena.

AB - The second messenger cyclic guanosine 3′5′ monophosphate (cGMP) and its downstream effector protein kinase G (PKG) have been discovered more than 40 years ago. In vessels, PKG1 induces smooth muscle relaxation in response to nitric oxide signalling and thus lowers systemic and pulmonary blood pressure. In platelets, PKG1 stimulation by cGMP inhibits activation and aggregation, and in experimental models of heart failure (HF), PKG1 activation by inhibiting cGMP degradation is protective. The net effect of the above-mentioned signalling is cardiovascular protection. Yet, while modulation of cGMP-PKG has entered clinical practice for treating pulmonary hypertension or erectile dysfunction, translation of promising studies in experimental HF to clinical success has failed thus far.With the advent of new technologies, novel mechanisms of PKG regulation, including mechanosensing, redox regulation, protein quality control, and cGMP degradation, have been discovered. These novel, non-canonical roles of PKG1 may help understand why clinical translation has disappointed thus far. Addressing them appears to be a requisite for future, successful translation of experimental studies to the clinical arena.

KW - Cardiac mechanosensing

KW - CGMP-dependent protein kinase type 1

KW - Phosphodiesterase

KW - Proteasome

KW - Protein kinase G

KW - Redox regulation

UR - http://www.scopus.com/inward/record.url?scp=85007391158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007391158&partnerID=8YFLogxK

U2 - 10.1093/cvr/cvw107

DO - 10.1093/cvr/cvw107

M3 - Review article

C2 - 27297890

AN - SCOPUS:85007391158

VL - 111

SP - 154

EP - 162

JO - Cardiovascular Research

JF - Cardiovascular Research

SN - 0008-6363

IS - 2

ER -